For a 250 mg immediate-release film-coated tablet with a target core weight of 350 mg, the API lot selection is governed by particle size distribution, residual water, and flow function coefficient after granulation rather than by chemical purity alone. Laser diffraction particle size data under USP <429> for wet-granulation-grade azithromycin dihydrate commonly show a D50 of 10–30 µm and a D90 below 200 µm; material retained on a 100-mesh sieve above 5.0% w/w after a trial granulation is typically milled again to avoid slow dissolution and weight variation during compression. A starting dry-blend matrix containing azithromycin dihydrate equivalent to 250 mg base per 350 mg core can be set at 74.9% w/w azithromycin dihydrate, 10.6% w/w microcrystalline cellulose PH102, 8.5% w/w lactose monohydrate, 3.0% w/w croscarmellose sodium, 2.0% w/w povidone K30, and 1.0% w/w magnesium stearate. The povidone K30 is added as an 8% w/w aqueous binder solution at a liquid-to-solid ratio of 0.10–0.12; high-shear granulation is carried out in a top-driven vertical granulator at impeller speed 300–500 rpm and chopper speed 1500 rpm until the wet mass reaches a dense, short-textured endpoint. The wet granules are screened through a 1.0 mm stainless-steel sieve and dried in a fluid-bed dryer with inlet air at 55–60 °C until loss on drying is 1.5–2.5%. The dried granules are milled through a 0.8 mm screen and blended with magnesium stearate for 3–5 minutes only; over-lubrication beyond 5 minutes produces a hydrophobic film that lengthens the dissolution lag phase. Compression on a rotary tablet press with pre-compression force 5 kN and main compression force 12–25 kN, at turret speed 30–60 rpm, produces cores with hardness 80–150 N, friability not more than 1.0% by USP <1216>, and disintegration time below 15 minutes by USP <701>. The dissolution acceptance criterion is Q=80% at 30 minutes using USP <711> Apparatus II at 75 rpm in 900 mL of pH 6.0 phosphate buffer. Film coating is performed with a ready-to-use polyvinyl alcohol–based coat at 3–4% w/w core weight gain, inlet air 60–70 °C, bed temperature 40–45 °C, spray rate 8–15 g/min per gun, and atomizing air pressure 1.0–1.5 bar. Elemental impurities are controlled by ICH Q3D, and residual solvents are controlled by ICH Q3C. Operational boundary: if final blend moisture exceeds 4.0% w/w, sticking and picking on the upper punch become detectable within 30 minutes of continuous compression, especially when tablet press tooling is maintained at 30–35 °C.

Why Does Dry Capsule Filling Shift the Critical Quality Attribute from Compactability to Plug Retention?

When the same 250 mg dose is filled into an HPMC capsule shell at a target fill weight of 350 mg, the powder blend no longer needs high compactability but must retain a plug during transfer from the dosator or tamping segment. In this configuration, azithromycin dihydrate equivalent to 250 mg base is set at 74.9% w/w, with 12.9% w/w pregelatinized starch, 9.0% w/w lactose monohydrate 200 mesh, 2.0% w/w croscarmellose sodium, 0.2% w/w colloidal silicon dioxide, and 1.0% w/w magnesium stearate. The blend is prepared in a 25 rpm V-blender for 15 minutes after the API and glidant have been passed through a 30-mesh screen. Capsule filling on a tamping-pin machine is run with plug compression force between 50 and 150 N; lower force produces weight variation above 2.0% RSD across 20 capsules, while higher force can densify the plug and delay disintegration. HPMC shells are preferred when ambient relative humidity exceeds 60% because gelatin shells with moisture 13–16% w/w can transfer water to croscarmellose sodium and cause localized aggregation. The filled capsule is tested by USP <711> Apparatus II at 75 rpm in 900 mL pH 6.0 phosphate buffer with the same Q=80% at 30 minutes. Residual solvent limits follow ICH Q3C; if isopropyl alcohol is used for granulation, its class 3 limit of 5000 ppm must be verified in the final capsule. Elemental impurities are controlled by ICH Q3D.

When the finished dose form is a dry granule for oral suspension intended to yield 100 mg/5 mL after reconstitution, the process chain moves from tablet compactability to granule porosity, sedimentation volume, and taste-masked coating integrity. The formulation is built on a sucrose or sorbitol matrix at 60–75% w/w of the dry fill, with sodium phosphate dibasic or citric acid buffer at 2–5% w/w to achieve a reconstituted suspension pH of 7.0–8.0, xanthan gum at 0.2–0.5% w/w as the suspending agent, povidone K30 at 2–3% w/w as binder, sodium benzoate at 0.1–0.2% w/w as preservative, and colloidal silicon dioxide at 0.3–0.5% w/w as an anticaking agent. Azithromycin is practically insoluble at neutral pH, but the phosphate-buffered environment reduces the concentration of dissolved free base in the reconstituted vehicle, which is a processing lever used to suppress bitterness. For additional taste masking in pediatric or geriatric granule products, the API-containing granules are coated in a Wurster fluid-bed column with amino methacrylate copolymer at 5–10% w/w dry weight gain; inlet air is held at 50–60 °C, product temperature at 30–35 °C, spray rate at 5–10 g/min per nozzle, and the coated granules are cured for 30–60 minutes at 40 °C. After drying to a loss-on-drying of 0.8–1.5%, the granules are sieved to 0.5–2.0 mm and filled into sachets by auger filler with mass variation not more than 5.0% RSD. At reconstitution, the suspension is shaken for 30 seconds and allowed to stand; a sedimentation volume ratio of not less than 0.8 after 2 hours and resuspendability within 5 manual inversions are used as batch release indicators. Dissolution testing is conducted in pH 6.0 phosphate buffer under USP <711>; the acceptance criterion must match the current compendial monograph, and coating levels above 10% w/w can push the release below the Q value and create a batch rejection risk. Sachet filling is performed under FDA 21 CFR 211; elemental impurities are controlled by ICH Q3D.

If a 500 mg Vial Requires Sterile Lyophilization, pH Control and Endotoxin Limits Override Particle Flow Considerations

Sterile azithromycin for injection is manufactured as a lyophilized powder in a 10 mL Type I glass vial, not as a ready-to-use solution, because azithromycin dihydrate is practically insoluble in water at neutral pH. The bulk solution is prepared by dissolving the API in water for injection acidified with citric acid, followed by pH adjustment with sodium hydroxide to 6.5–7.5; the dissolved acid salt allows sterile filtration through a 0.22 µm PVDF membrane before the fill. In the lyophilized cake, citric acid is present at 2–5% w/w, and sodium hydroxide quantity is expressed as pH adjustment rather than fixed weight. A fill volume of 5.0 mL per vial is used to deliver 500 mg azithromycin. Endotoxin content in the incoming API is controlled at 0.25 EU/mg by USP <85>, bioburden before filtration is held below 10 CFU/100 mL, and sterility of the finished cake is verified by USP <71> and Ph. Eur. 2.6.1. The lyophilization cycle freezes the filled vials at -40 °C, then primary drying is run from -20 °C to 0 °C at chamber pressure 80–150 mTorr, and secondary drying is held at 25 °C for 6–10 hours. The release limit for cake moisture is ≤2.0% w/w because residual water above this level shortens the reconstituted solution’s chemical stability window and may increase degradation of the lactone ring. Reconstitution with 4.8 mL sterile water for injection produces a 100 mg/mL solution; manual or automated swirling should achieve complete dissolution in ≤2 minutes. For intravenous infusion, the concentrated solution is further diluted to 1.0–2.0 mg/mL in normal saline or 5% dextrose injection; concentrations above 2.0 mg/mL are an operational boundary because of infusion-site tolerability and osmolality constraints. Aseptic filling is performed in an EU GMP Annex 1 Grade A zone under ISO 14644-1 Class 5 conditions; settle plates are exposed for 4 hours with an action limit of ≤1 CFU/plate. Particulate matter after reconstitution and dilution is controlled by USP <788> for large-volume parenterals and USP <789> for small-volume parenterals, with subvisible particle limits of 6000 particles ≥10 µm and 600 particles ≥25 µm per container.

Single-Dose Extended-Release Oral Suspension: Coated Beads and Gastric Retention-Dependent Release

In a single-dose 2 g azithromycin extended-release oral suspension, the formulation strategy is shifted from immediate-release granulation to fluid-bed drug layering and release-modifying polymer coats; published data for this specific configuration is limited, so the following process ranges are drawn from macrolide coated-bead manufacturing and must be verified against the current compendial monograph. Azithromycin dihydrate is layered onto 20–25 mesh sugar spheres from an aqueous suspension containing hydroxypropyl methylcellulose as a 5% w/w binder. The drug-loaded cores are then coated in a Wurster column with ethylcellulose or methacrylic acid copolymer dispersion at a polymer-to-drug ratio of 0.05:1 to 0.2:1 w/w; triethyl citrate at 10–20% w/w of polymer solids is added as plasticizer, and talc at 50–100% w/w of polymer solids prevents bead agglomeration during the coating run. Inlet air temperature is maintained at 55–65 °C, product temperature at 30–35 °C, and spray rate at 5–10 g/min per nozzle; coated beads are cured at 40 °C for 2 hours. The cured beads are filled as a dry powder into a bottle of sufficient size to permit reconstitution to 60 mL with purified water, yielding a 2 g azithromycin dose. Dissolution for this extended-release product uses USP <711> with pH 6.0 phosphate buffer; because release-rate specifications are formulation-specific, the acceptance criterion must be taken from the current USP monograph, and any change in polymer source or bead size distribution should trigger a dissolution profile comparison. Residual solvent control follows ICH Q3C for the coating solvent, and loss on drying of the finished powder is held below 1.5% w/w to prevent irreversible aggregation of the coated beads during storage.